GSK Plans £1 Bil. In Cuts As Respiratory Strategy Fails To Deliver
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain’s biggest drug maker said it will cut costs by £1 billion in three years as sales of its blockbuster Advair continued to fall under increasing pricing pressure; the company also unveiled key management changes, including within its top R&D slots.